Cargando…

Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAF(V600E)-Mutant Advanced Papillary Thyroid Carcinoma

SIMPLE SUMMARY: The BRAF(V600E) point mutation is the most common driver mutation in papillary thyroid carcinoma (PTC) and is known to be associated with aggressive clinical features. However, the negative prognostic impact of BRAF(V600E) on PTC mostly depends on tumor characteristics, not on itself...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Eyun, Jin, Meihua, Jang, Ahreum, Jeon, Min Ji, Song, Dong Eun, Yoo, Hye Jin, Kim, Won Bae, Shong, Young Kee, Kim, Won Gu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616313/ https://www.ncbi.nlm.nih.gov/pubmed/34831001 http://dx.doi.org/10.3390/cancers13225846

Ejemplares similares

Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas
por: Jin, Meihua, et al.
Publicado: (2021)

Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis
por: Ahn, Jonghwa, et al.
Publicado: (2020)

Expression of NF2 Modulates the Progression of BRAF(V600E) Mutated Thyroid Cancer Cells
por: You, Mi-Hyeon, et al.
Publicado: (2019)

Quality of Life in Patients with Papillary Thyroid Microcarcinoma According to Treatment: Total Thyroidectomy with or without Radioactive Iodine Ablation
por: Ahn, Jonghwa, et al.
Publicado: (2020)

Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm
por: Oh, Hye-Seon, et al.
Publicado: (2018)

MON-494 Quality of Life in Patients with Papillary Thyroid Microcarcinoma According to the Treatment: Total Thyroidectomy Versus Total Thyroidectomy with Radioactive Iodine Remnant Ablation
por: Ahn, Jonghwa, et al.
Publicado: (2020)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Graves’ disease diagnosed in remnant thyroid after lobectomy for thyroid cancer
por: Jin, Meihua, et al.
Publicado: (2022)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Gender-Dependent Reference Range of Serum Calcitonin Levels in Healthy Korean Adults
por: Song, Eyun, et al.
Publicado: (2021)

Prevalence of BRAF(V600E) Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF(V600E) Prevalent Area
por: Kim, Hyereen, et al.
Publicado: (2018)

Long-term follow-up result of antithyroid drug treatment of Graves’ hyperthyroidism in a large cohort
por: Jin, Meihua, et al.
Publicado: (2023)

Cross-Regulation between Oncogenic BRAF(V600E) Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma
por: Lee, Seong Jin, et al.
Publicado: (2011)

BRAF(V600E) Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
por: Park, Joonseon, et al.
Publicado: (2023)

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
por: Kim, Min Jhi, et al.
Publicado: (2022)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy
por: Jin, Meihua, et al.
Publicado: (2020)

Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
por: Jeon, Min Ji, et al.
Publicado: (2021)

Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
por: Jeon, Min Ji, et al.
Publicado: (2022)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
por: Park, Kyoung Sik, et al.
Publicado: (2021)

Solitary Skin Metastasis of Papillary Thyroid Carcinoma
por: Kwon, Hyemi, et al.
Publicado: (2014)

The Frequency and Clinical Implications of the BRAF(V600E) Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades
por: Hong, A Ram, et al.
Publicado: (2014)

Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
por: Kim, Sue Youn, et al.
Publicado: (2020)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Silencing FOXP2 reverses vemurafenib resistance in BRAF(V600E) mutant papillary thyroid cancer and melanoma cells
por: Jiang, Suyuan, et al.
Publicado: (2022)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

BRAF V600E and lymph node metastases in papillary thyroid cancer
por: Chen, Pan, et al.
Publicado: (2020)

Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma
por: Jeon, Min Ji, et al.
Publicado: (2016)

BRAF(V600E) mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features
por: Shi, Chenlei, et al.
Publicado: (2020)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

Complete response of metastatic BRAF V600-mutant anaplastic thyroid cancer following adjuvant dabrafenib and trametinib treatment: A case report
por: Lee, Sang Jae, et al.
Publicado: (2023)

Prognostic parameters for recurrence of papillary thyroid microcarcinoma
por: Kim, Tae Yong, et al.
Publicado: (2008)

Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
por: Kim, Woon Won, et al.
Publicado: (2018)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
por: Yan, Changjiao, et al.
Publicado: (2019)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

Sacral metastases in a patient with BRAF V600E+ papillary thyroid carcinoma
por: Bhethanabotla, Rohith M, et al.
Publicado: (2023)

The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma
por: Scheffel, Rafael Selbach, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5reulml9pc8a2eejcpg06mqeb5